Recon: Woodcock, Marks recuse themselves from COVID-19 vaccine approval decisions; FDA approves Lynparza for prostate cancer

• Amid conflict-of-interest criticisms, top FDA officials recuse themselves from Covid-19 vaccine approvals (STAT)
• Vaccine experts say Moderna didn’t produce data critical to assessing Covid-19 vaccine (STAT)
• Prototype Vaccines Protect Monkeys From Coronavirus (NYTimes) (Reuters)
• Inovio says COVID-19 vaccine produces antibodies in mice, guinea pigs (Reuters)
• Lonza CEO says on pace to make Moderna trial vaccine in June/July: CNBC (Reuters)
• Amid Hydroxychloroquine Uproar, Real Studies of Drug Are Suffering (NYTimes) (NPR)
• The Risks of Trump’s Hydroxychloroquine Hype (NYTimes)
• CEO tapped by Trump to make generic drugs during pandemic has a dicey track record (STAT)
• AstraZeneca-Merck's Lynparza gets FDA nod for prostate cancer treatment (Reuters) (Endpoints) (FDA)

• WHO chief says he will keep leading virus response after Trump threat (Reuters)
• Fujifilm shares fall after report Avigan not showing clear efficacy in some coronavirus trials (Reuters)
• China Leads The Worldwide Race To Develop A COVID-19 Vaccine (NPR)
• Swiss seek to secure COVID-19 vaccine amid hoarding fears (Reuters)
• Brazil widens use of malaria drugs to treat mild coronavirus cases (Reuters)
• Thailand says it expects coronavirus vaccine next year after tests in mice (Reuters)
• Coronavirus behaving differently in China's northeast clusters, expert says (Reuters)
• Japan pharma: race to escape (Financial Times)
• Raids Reveal Massive Fentanyl Production in Myanmar (NYTimes)

• CDC quietly releases detailed guidelines for reopening America (CNBC)
• 'We've been muzzled': CDC sources say White House putting politics ahead of science (CNN)
• NIH to study how COVID-19 pandemic may have affected pregnancy outcomes in US (Reuters)
• Coronavirus particles spread by talking can remain in the air for up to 14 minutes, NIH researchers find (CNBC)
• Florida Dismisses A Scientist For Her Refusal To Manipulate State's Coronavirus Data (NPR)
• MHLW Adds Veklury in Updated COVID-19 Treatment Guide (PharmaJapan)
• Dutch farm worker contracted coronavirus from mink: agriculture minister (Reuters)
• Argentine scientists working on low-cost two-hour coronavirus test (Reuters)
• Bolivian city gives out free doses of de-worming drug in bid to combat coronavirus (Reuters)
• Brazil suffers record coronavirus deaths, Trump mulls travel ban (Reuters)

• Real-time data are essential for Covid-19. They’re just as important for the opioid overdose crisis (STAT)
• Cash-strapped Clovis bums out investors with $85M offering (Fierce)
• Biotech companies raise cash as coronavirus updates lift stocks (BioPharmaDive)
• Two years of halting progress and high turnover preceded Atul Gawande’s exit as Haven CEO (STAT)
• A little-known biotech running low on cash looks to get its own $100M IPO from pandemic market (Endpoints)
• Ally Bridge joins Bain in $120M bet that speeding up manufacturing QC can hit big in post-pandemic world (Endpoints)
• George Church spinoff swallows a key manufacturing partner as it preps CRISPR-edited pig organs for animal testing (Endpoints)
• Flush with $165M IPO cash, Zentalis entices Tybourne, OrbiMed to fund a $20M China joint venture (Endpoints)
• Pharmasset co-founder jumps into Covid-19 fight, with a new company and $215 million to get there (Endpoints)
• Silence Therapeutics wants to list on Nasdaq while pursuing new deals; Surface Oncology inks latest Keytruda collaboration (Endpoints)
• Samsung Bioepis Announces Four-Year Follow-Up Data for its Trastuzumab Biosimilar and 24-Week Interim Results from Phase 3 Trial of its Proposed Ranibizumab Biosimilar (Big Molecule Watch)

• South Korea adds renewal requirement for new medical device authorizations (Emergo)
• Investors bet diabetes tech immune to full brunt of COVID-19 (MedtechDive)
• AdvaMed, health systems set ground rules for return of sales reps (MedtechDive)
• Thermedical’s Groundbreaking SERF Ablation System Earns FDA’s Breakthrough Device Designation (Press)
• Baxter Receives CE Marking and Australian Regulatory Approval for Evo IQ Syringe Infusion System, Building on Smart Pump Platform (Press)

• Johnson & Johnson to End Talc-Based Baby Powder Sales in North America (NYTimes)
• Broad, UC Each Tell PTAB It Invented CRISPR First (Law360)
• J&J Unit Must Face Class Claims Over 'Rapid Release' Tylenol (Law360)
• European Medicines Agency and EuropaBio – 26 May 2020 (EMA)
• Australian Regulatory Guidelines for Listed Medicines and Registered Complementary Medicines (TGA)
• Federal legislation to protect health data has made little progress. Will that change in the Covid-19 era? (STAT)
• Effective field safety notices (FSNs): guidance for manufacturers of medical devices (MHRA)